The Efficacy of Posterior Subtenon Triamcinolone Acetonide Injection in Treatment of Irvine-Gass Syndrome

Abstract

<i>Purpose</i>: To evaluate the efficacy and safety of posterior 40 mg subtenon triamcinolone acetonide (PST) injection in treating Irvine-Gass syndrome.<i>Methods</i>: The retrospective study included 21 patients (mean age: 76 ± 8.2) with a treatment-naïve eye subjected to topical anesthesia and injection of 40 mg/ml triamcinolone via a blunt tip SubTenon cannula through a single inferonasal peritomy. Best corrected visual acuity (BCVA; logMAR), intraocular pressure (IOP), biomicroscopic and funduscopic findings, and optical coherence tomography (OCT) measurements were recorded.<i>Results</i>: Baseline central macular thickness decreased from 431 ± 136 µm to 300 ± 67 µm (1st month; <i>p</i> = .002), to 292 ± 56 µm (3rd month; <i>p</i> = .002), and to 299 ± 66 µm (6th month; <i>p</i> = .005). Mean BCVA increased from 0.71 ± 0.23 to 0.27 ± 0.11, 0.19 ± 0.06, and 0.24 ± 0.17, respectively (all visits; <i>p</i> < 0.001). Mean IOP values did not change significantly (<i>p</i> = .12).<i>Conclusion</i>: PST injection is an effective and safe treatment for Irvine-Gass syndrome.